Phase II Study of BNC210 in PTSD (RESTORE)

A Randomized, Double-blind, Placebo-controlled Phase II Study of BNC210 in Adults With Post-Traumatic Stress Disorder (PTSD).

This is a randomized, double-blind, placebo-controlled study, evaluating the effects of BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).

The secondary objectives of the study are to evaluate the effects of BNC210 on anxiety, depression, global functioning and patient reported outcomes in patients with PTSD. Safety and tolerability of BNC210 will also be assessed. Study participants will receive 12 weeks of blinded treatment followed by a 3 week follow-up period.

Study Overview

• Status: Completed
• Conditions: Post-Traumatic Stress Disorder
• Intervention / Treatment: Drug: Placebo; Drug: BNC210

• Study Type: Interventional
• Enrollment (Actual): 193
• Phase: Phase 2

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Penrith, New South Wales, Australia, 2751
  • Queensland
    • Auchenflower, Queensland, Australia, 4066
    • Toowong, Queensland, Australia, 4066
  • South Australia
    • Elizabeth Vale, South Australia, Australia, 5112
  • Victoria
    • St Kilda, Victoria, Australia, 3004
• United States
  • California
    • Oceanside, California, United States, 92056
    • Rancho Mirage, California, United States, 92270
    • Redlands, California, United States, 92374
    • Riverside, California, United States, 92506
  • Florida
    • Gainesville, Florida, United States, 32607
    • Jacksonville, Florida, United States, 32256
    • Lauderhill, Florida, United States, 33309
    • North Miami, Florida, United States, 33161
    • Oakland Park, Florida, United States, 33334
    • Orlando, Florida, United States, 32801
  • Illinois
    • Hoffman Estates, Illinois, United States, 60169
  • Kansas
    • Overland Park, Kansas, United States, 66211
  • Massachusetts
    • New Bedford, Massachusetts, United States, 02740
  • Nebraska
    • Lincoln, Nebraska, United States, 68526
  • Nevada
    • Las Vegas, Nevada, United States, 89102
  • New Jersey
    • Berlin, New Jersey, United States, 08009
  • Ohio
    • Canton, Ohio, United States, 44718
  • Tennessee
    • Memphis, Tennessee, United States, 38119
  • Texas
    • Dallas, Texas, United States, 75231
    • San Antonio, Texas, United States, 78229

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

• Signed and dated informed consent.
• Male or female between 18 and 70 years of age, inclusive.
• Diagnosed with current PTSD as defined by the CAPS-5 for DSM-5.

• Currently not using any psychiatric medications except for:

  • No more than one selective serotonin reuptake inhibitor (SSRI) (fluvoxamine is excluded) or serotonin noradrenaline reuptake inhibitor (SNRI) within the licensed prescribing dose range. Subjects must have been on a stable dose for at least 3 months prior and through Screening, with the intent to remain on the same dose through to Week 16.
  • As needed (PRN) use of benzodiazepines (BZD) at a frequency not exceeding 2 days per week in the 3 months prior to Screening. The total dose must not exceed 30 mg/day in diazepam equivalents.
• Subjects not currently receiving psychotherapy except long term supportive counseling or subjects that have received intensive regular psychotherapy for a minimum of three months prior to Screening.
• Females of childbearing potential must have a negative serum pregnancy. Females not of childbearing potential must be postmenopausal. Sterilized male patients must be at least 1 year post-vasectomy to be considered of non-child bearing potential. Females and males of childbearing potential must agree to use two effective methods of contraception.

Key Exclusion Criteria

• Current and ongoing exposure to the trauma that caused the PTSD.
• Failed more than three trials of antidepressant medication(s) prescribed for the treatment of PTSD. Each trial must have lasted at least 6 weeks to be considered a failed attempt. A trial that was terminated due to intolerability or side effects does not constitute a failed attempt.
• The use of psychiatric medications within 2 weeks of Screening except for SSRIs, SNRIs or limited PRN BZD use as per inclusion criterion 4. Restricted psychiatric medications include (but are not limited to) antidepressants not allowed by inclusion criterion 4, antianxiety drugs (except limited BZD use per inclusion criterion 4), mood stabilizers, stimulants, antipsychotics, hypnotics and acetylcholinesterase inhibitors.
• History of significant traumatic brain injury.
• Depression as measured by Montgomery-Äsberg depression scale (MADRS) rating > 23.
• Bipolar and psychotic disorders as identified at Screening using the MINI International Neuropsychiatry Interview (V7.0) (M.I.N.I).
• A score ≥ 7 on the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) at Screening.
• History of seizure disorders, uncontrolled sleep apnoea or severe neurologic disease.

• Increased risk of suicide, defined as:

  • Any previous suicide attempt disclosed by the participant at Screening using the Columbia Suicide Severity Rating Scale (C-SSRS).
  • Any suicidal ideation with intent (yes to item 4 and / or 5) or suicidal behavior in the past year, as captured at Screening using the C-SSRS.
  • A score > 4 on item 10 of the MADRS at Screening.
• The use of alprazolam or flunitrazepam within 3 months of Screening.
• Any clinically significant abnormalities in laboratory test results, vitals signs, or ECG at Screening.
• Positive result for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) at Screening.
• Any moderate to severe substance use disorder (any type) in the 12 months prior to Screening as identified by the DSM-5 using the M.I.N.I (V7.0).
• Current Australian serving Defense personnel or any member of the US military currently serving on active duty.
• Participants involved with ongoing insurance or workplace claims that in the opinion of the Investigator are likely to have an impact on the mental health, presentation or capacity of the patient to engage in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BNC210 600 mg b.i.d.; Suspension administered orally for 12 weeks.	Drug: BNC210
Experimental: BNC210 300 mg b.i.d.; Suspension administered orally for 12 weeks.	Drug: BNC210
Experimental: BNC210 150 mg b.i.d.; Suspension administered orally for 12 weeks.	Drug: BNC210
Placebo Comparator: Placebo b.i.d.; Suspension administered orally for 12 weeks.	Drug: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score	Investigator-rated PTSD symptom severity. The range for the Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5)Total Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease.	12 weeks.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5).	Self-reported PTSD symptom severity. The range for the Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5) Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease.	12 weeks.
Montgomery- Åsberg Depression Rating Scale (MADRS).	Depression severity. The range for the Montgomery- Åsberg Depression Rating Scale (MADRS) is 0-60, with a higher score meaning a higher severity of disease.	12 weeks.
Hamilton Anxiety Rating Scale (HAM-A).	Anxiety severity. The range for the Hamilton Anxiety Rating Scale (HAM-A) is 0-56, with a higher score meaning a higher severity of disease.	12 weeks
Clinical Global Impressions - Severity Scale (CGI-S).	Clinician's assessment of global symptom severity using the Clinical Global Impressions - Severity Scale (CGI-S).	12 weeks
Clinical Global Impressions - Improvement Scale (CGI-I).	Clinician's assessment of global symptom improvement using the Clinical Global Impressions - Improvement Scale (CGI-I).	12 weeks
Patient Global Impressions - Severity Scale (PGI-S).	Self-reported global symptom severity using the Patient Global Impressions - Severity Scale (CGI-S).	12 weeks.
Patient Global Impression - Improvement Scale (PGI-I).	Self-reported global symptom improvement using the Patient Global Impression - Improvement Scale (PGI-I).	12 weeks.
Assessment of Quality of Life (AQoL-8D).	Quality of Life. The range for the Assessment of Quality of Life (AQoL-8D) score is 35-176, with a higher score meaning a lower quality of life.	12 weeks.
Social Functioning: Sheehan Disability Scale (SDS).	Social functioning. The range for the Total Score on the Sheehan Disability Scale (SDS) is 0-30, with a higher score meaning a higher degree of impairment.	12 weeks.
Sleep Monitoring: Pittsburgh Sleep Quality Index (PSQI).	Sleep quality and duration. The range for the Pittsburgh Sleep Quality Index (PSQI) score is 0-21, with a higher score meaning a worse level of sleep quality	12 weeks.
CANTAB (Cambridge Neuropsychological Test Automated Battery) Cognitive Assessment	The CANTAB global composite score is based on the Z scores for CANTAB outcome measures (PAL first attempt memory score (PALFAMS), PAL total errors adjusted (PALTEA), SWM between errors (SWMBE), SWM strategy (SWMS), RVP A' prime (RVPA), RVP median latency (RVPMDL). Specifically, the global composite score of cognitive function is as follows: CANTAB global composite score of cognitive function = (ZPALFAMS + ZPALTEA + ZSWMBE + ZSWMS + ZRVPA + ZRVPMDL) /8 (higher is better) A Z-score of 0 represents the population mean. A Z-score above 0 indicates cognition higher than the population mean and Z-score below 0 indicates cognition lower than the population mean	12 Weeks

Collaborators and Investigators

• Sponsor: Bionomics Limited

Study record dates

Study Major Dates

• Study Start (Actual): June 30, 2016
• Primary Completion (Actual): July 5, 2018
• Study Completion (Actual): July 25, 2018

Study Registration Dates

• First Submitted: September 1, 2016
• First Submitted That Met QC Criteria: October 13, 2016
• First Posted (Estimate): October 14, 2016

Study Record Updates

• Last Update Posted (Estimate): February 27, 2023
• Last Update Submitted That Met QC Criteria: February 23, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Trauma and Stressor Related Disorders; Stress Disorders, Traumatic; Stress Disorders, Post-Traumatic
• Other Study ID Numbers: BNC210.007

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes